PDCD1 and cervical carcinoma: Currently, immune checkpoint inhibitors (Schumacher and Schreiber, 2015), especially PD-1/PD-L1 inhibitors (Constantinidou et al., 2018), have achieved favorable efficacy in treating multiple solid tumors (Gettinger et al., 2018), including cervical cancer (Borcoman and Le Tourneau, 2017).